PLEASANTON, Calif. and SINGAPORE, Nov. 19, 2013 /PRNewswire/ -- TriReme Medical, LLC. announced today that its Japanese partner, Century Medical, Inc. (CMI), has received Shonin approval for the GliderXtreme™ PTA catheter for the treatment of peripheral arterial blockages, a widespread disease impacting over 200 million people worldwide1. With its low-profile nitinol shaft and proprietary "slide-lock" design, GliderXtreme™ is designed to address complex lesions in the peripheral vasculature. The innovative features of GliderXtreme™ produce a balloon catheter with exceptional pushability and crossability, providing physicians with the confidence needed to begin and finish even the toughest cases.
"Peripheral arterial disease is a growing health care concern in Asia. GliderXtreme™ was custom designed to meet the clinical needs and exacting standards of the Japanese marketplace. We are proud to receive this regulatory approval," stated Eitan Konstantino PhD, President and CEO of TriReme. "This milestone represents yet another step in the Asia-focused expansion strategy of TriReme."
"Representing the latest in peripheral balloon technology, GliderXtreme™ will enable Japanese physicians to treat complex lesions both above and below the knee," explained Akira Hoshino, President and CEO of CMI. "This is the second product approved as a result of our collaboration with TriReme Medical."
Based in Pleasanton, California, TriReme Medical, LLC is a wholly-owned subsidiary of the Singapore based QT Vascular, Ltd. TriReme is dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease.
|SOURCE TriReme Medical, Inc.|
Copyright©2012 PR Newswire.
All rights reserved